Authors: A.N. Belousov
Affilation: Laboratory of Applied Nanotechnology, Ukraine
Pages: 486 - 488
Keywords: magnetite nanoparticles, hemolysis, erythrocytes, apoptosis
In Ukraine the first medical nanotechnology drugs were synthesized and patented in 1998 (http://www.nanolab.com.ua). These are such drugs as intracorporeal biocorrector (ICBB), magnet-controlled sorbent (MCS-B) and Micromage-B (Belousov A.N., 1997, 1998, 2000). Basis of the drugs is magnetite nanoparticles (Fe3O4) with the size ranging from 6 till 12 nm. Presence of adsorption layer provides high sorption activity for the magnetite nanoparticles. The total sorption surface of the magnetite nanoparticles ranges from 800 to 1200 m2/g, and intensity of the magnetic field induced by each magnetite nanoparticle is 300-400 kA/m. The main purpose of the work is to reduce hemolysis of erythrocytes by means of nanoparticles of magnet-controlled sorbent (MCS-B). To fulfill the aim the following tasks are to be solved: - to determine the dependence between time of appearing hemolysis and amount of processing of blood with MCS-B; - to investigate activity of transport adenosinetriphosphatese of erythrocytes: Na, K - ATPHese and Ca, Mg – ATPHese; - to find optimum amount processing of blood with nanoparticles of magnet-controlled sorbent (MCS-B). This work for the first time describes (in comparison with control) the indices characterizing dependence of time of appearing hemolysis on frequency rate of processing the blood by nanoparticles of MCS-B. It was established, that extracorporally processing the blood by nanoparticles of MCS-B reliably reduces activity of Ca, Mg - ATPHese of erythrocytes. The researches has proved that now nanoparticles of MCS-B are able not only to considerably reduce hemolysis, and thereby prolong storage time of the blood, influence activity of adenosinetriphosphateses of erythrocytes, regulate transmembrane exchange (Belousov A.N., 2004), but also to extracorporally influence cellular apoptosis. Thus: 1. The optimum frequency rate (1-2 times) of processing the blood by nanoparticles of MCS-B inhibiting hemolysis was found. 2. It was established, that activity of Ca, Mg – ATPHese of erythrocytes decreases with increasing frequency rate of processing the blood by nanoparticles of MCS-B. 3. Activity of Na, K - ATPHese of erythrocytes in extracorporally processing the blood by nanoparticles of MCS-B does not change (p> 0.05). 4. The minimum indicator of activity of Ca, Mg - ATPHese is 6.01±1.2 protein mmol/mg in mines which time of appearing hemolysis practically does not differ from the control was found.